Acquiring Company
Mankind Pharma
Acquired Company
Prolijune Lifesciences Private Limited
New DelhiIndiaBiotechnologyHealth CarePharmaceuticalBiotechnologyPharmaceuticalDescription
Mankind Pharma's board approved a scheme to merge wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent, with an appointed date of April 1, 2027. The merger is subject to statutory approvals, including from the National Company Law Tribunal, where applicable. The board also noted a separate proposed merger of Upakarma Ayurveda and Mankind Consumer Products, approved by their boards on October 26, 2026.
Who to call at Mankind Pharma, and when
When Mankind Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Mankind Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mankind Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mankind Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mankind Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Prolijune Lifesciences Private Limited?
Prolijune Lifesciences Private Limited was acquired by Mankind Pharma, based in New Delhi. The deal was reported on October 26, 2026. Mankind Pharma is a pharmaceutical company that has completed the transaction to acquire Bharat Serums and Vaccines Ltd (BSV), for a consideration of ₹13,768 crore. Mankind Pharma is privately held and operates in Biotechnology.
When did Mankind Pharma acquire Prolijune Lifesciences Private Limited?
Mankind Pharma's acquisition of Prolijune Lifesciences Private Limited was reported on October 26, 2026. Mankind Pharma's board approved a scheme to merge wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent, with an appointed date of April 1, 2027. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Prolijune Lifesciences Private Limited do?
Prolijune Lifesciences Private Limited is a wholly owned subsidiary of Mankind Pharma. Its board-approved scheme provides for merger into the parent company, with an appointed date of April 1, 2027. It is privately held, operating in Biotechnology, and is based in India.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.